OBJECTIVE: To assess plasma and vaginal inflammation in three antenatal groups (HIV-uninfected women, HIV-infected women entering care on preconceptional ART, and HIV-infected women not on preconceptional ART) and whether these measures are associated with spontaneous preterm birth (sPTB). DESIGN: Case--control study nested within a pregnancy cohort in Lusaka, Zambia. METHODS: We analyzed 11 pro-inflammatory and two anti-inflammatory markers in 207 women with paired plasma and vaginal specimens collected between 16 and 20 gestational weeks. Among 51 HIV-infected women, we repeated the assays in 24-34-week samples. We used confirmatory factor analysis to create inflammation scores and compared them among the three groups. RESULTS: At baseline, HIV-infected women not on ART had higher vaginal pro-inflammatory scores than HIV-uninfected women [mean 0.37 (95% CI -0.06 to 0.80) vs. -0.02 (-0.32 to 0.27), P = 0.02]. In repeat testing, women not on preconceptional ART had an increase in vaginal inflammation between the baseline and 24-34-week visits compared with those continuing preconceptional ART [mean 0.62 (95% CI -0.80 to 4.20) vs. -0.07 (-2.78 to 2.11), P = 0.04]. In multivariate analyses, baseline vaginal inflammation predicted sPTB (aOR 1.5; 95% CI 1.0-2.3; P = 0.02). Plasma inflammation did not differ by HIV or ART exposure and was not associated with sPTB. CONCLUSION: Women not receiving ART at entry into pregnancy care had more vaginal inflammation than women entering on treatment. They also experienced an increase in vaginal inflammation between the two sampling timepoints, possibly as a consequence of ART initiation. Vaginal (but not systemic) inflammation was associated with sPTB and offers a potential mechanistic insight into this important adverse birth outcome.
OBJECTIVE: To assess plasma and vaginal inflammation in three antenatal groups (HIV-uninfected women, HIV-infected women entering care on preconceptional ART, and HIV-infected women not on preconceptional ART) and whether these measures are associated with spontaneous preterm birth (sPTB). DESIGN: Case--control study nested within a pregnancy cohort in Lusaka, Zambia. METHODS: We analyzed 11 pro-inflammatory and two anti-inflammatory markers in 207 women with paired plasma and vaginal specimens collected between 16 and 20 gestational weeks. Among 51 HIV-infected women, we repeated the assays in 24-34-week samples. We used confirmatory factor analysis to create inflammation scores and compared them among the three groups. RESULTS: At baseline, HIV-infected women not on ART had higher vaginal pro-inflammatory scores than HIV-uninfected women [mean 0.37 (95% CI -0.06 to 0.80) vs. -0.02 (-0.32 to 0.27), P = 0.02]. In repeat testing, women not on preconceptional ART had an increase in vaginal inflammation between the baseline and 24-34-week visits compared with those continuing preconceptional ART [mean 0.62 (95% CI -0.80 to 4.20) vs. -0.07 (-2.78 to 2.11), P = 0.04]. In multivariate analyses, baseline vaginal inflammation predicted sPTB (aOR 1.5; 95% CI 1.0-2.3; P = 0.02). Plasma inflammation did not differ by HIV or ART exposure and was not associated with sPTB. CONCLUSION: Women not receiving ART at entry into pregnancy care had more vaginal inflammation than women entering on treatment. They also experienced an increase in vaginal inflammation between the two sampling timepoints, possibly as a consequence of ART initiation. Vaginal (but not systemic) inflammation was associated with sPTB and offers a potential mechanistic insight into this important adverse birth outcome.
Authors: Ida Vogel; Alice R Goepfert; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Allison H Curry; Suzanne Cliver; William W Andrews Journal: J Reprod Immunol Date: 2007-04-17 Impact factor: 4.054
Authors: Brandie D Taylor; Claudia B Holzman; Raina N Fichorova; Yan Tian; Nicole M Jones; Wenjiang Fu; Patricia K Senagore Journal: Hum Reprod Date: 2013-02-15 Impact factor: 6.918
Authors: Marian Kacerovsky; Ivana Musilova; Tomas Bestvina; Martin Stepan; Teresa Cobo; Bo Jacobsson Journal: Fetal Diagn Ther Date: 2017-08-10 Impact factor: 2.587
Authors: Jose Villar; Aris T Papageorghiou; Hannah E Knight; Michael G Gravett; Jay Iams; Sarah A Waller; Michael Kramer; Jennifer F Culhane; Fernando C Barros; Agustín Conde-Agudelo; Zulfiqar A Bhutta; Robert L Goldenberg Journal: Am J Obstet Gynecol Date: 2011-10-25 Impact factor: 8.661
Authors: Jeffrey S A Stringer; Marie C Stoner; Margaret P Kasaro; Bellington Vwalika; Stephen R Cole Journal: Lancet HIV Date: 2017-04 Impact factor: 12.767
Authors: Joy E Lawn; Hannah Blencowe; Shefali Oza; Danzhen You; Anne C C Lee; Peter Waiswa; Marek Lalli; Zulfiqar Bhutta; Aluisio J D Barros; Parul Christian; Colin Mathers; Simon N Cousens Journal: Lancet Date: 2014-05-19 Impact factor: 79.321
Authors: Joan T Price; Bellington Vwalika; Katelyn J Rittenhouse; Humphrey Mwape; Jennifer Winston; Bethany L Freeman; Ntazana Sindano; Elizabeth M Stringer; Margaret P Kasaro; Benjamin H Chi; Jeffrey Sa Stringer Journal: Gates Open Res Date: 2020-01-24
Authors: Joan T Price; Bellington Vwalika; Michael France; Jacques Ravel; Bing Ma; Humphrey Mwape; Katelyn J Rittenhouse; Kristina De Paris; Marcia Hobbs; Julie A Nelson; Margaret P Kasaro; Elizabeth M Stringer; Jeffrey S A Stringer Journal: Sci Rep Date: 2022-05-20 Impact factor: 4.996